ChinaBio Today -- Last week was the quarterly high-water mark for earnings announcements in China Biotech. As a basic theme, the reports seemed each in their own way to reiterate the same message: the majority of China biopharmas reported higher revenues, though the good news was generally clouded by some less-than-ideal disclosure. Any decent novelist will attest that it is the variations to the theme that makes a story interesting, and we have tried to present the notable details of each earnings release.
